Abstract 81P
Background
mFOLFOX6 concurrent radiotherapy in the FOWARC study led to 27% of pCR rate in locally advanced rectal cancer (LARC). The total neoadjuvant treatment study (CAO/ARO/AIO-12) had compared the efficacy of chemoradiotherapy plus induction or consolidation chemotherapy. The result showed that consolidation chemotherapy led to higher pCR rate than that of induction chemotherapy. Here, we aimed to compare the efficacy of preoperative concurrent mFOLFOX6 chemoradiotherapy versus concurrent and consolidation chemotherapy during radiation as neoadjuvant treatment in locally advanced rectal cancer.
Methods
Prospectively maintained databases of patients from two clinical trials ( NCT01211210 and NCT02217020) underwent preoperative treatment for locally advanced rectal cancer were included. 143 patients received concurrent mFOLFOX6 chemoradiotherapy and TME surgery. 123 patients received concurrent and consolidation chemotherapy during radiation before TME. A comparative analysis was performed after the implementation of propensity score matching on the 2 main cohorts.
Results
A total of 266 patients were enrolled in the study. After propensity score matching, 180 patients were selected. 113 patients were comparable in the two groups. The pathologic complete response rate was comparable between the two groups (27.1% vs. 27.9%). And the tumor downstaging rate was also similar between the two groups (54.1vs. 59.1%). The compliance of chemotherapy was much better in concurrent chemoradiotherapy with mFOLFOX6 (93.5% vs. 39.5%). Higher incidence of grade 3/4neutropenia (16.1% vs. 30.1%, P < 0.01) was shown in concurrent chemoradiotherapy group than that of concurrent and consolidation chemoradiotherapy group.
Conclusions
Preoperative concurrent chemoradiotherapy with mFOLFOX6 showed similar efficacy with radiotherapy plus consolidation chemotherapy and higher compliance of chemotherapy. Long-term follow-up will assess whether the higher compliance would translates to better oncologic outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yanhong Deng.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract